The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells.
Open accessAbstract
The pathogenesis and etiology of Hodgkin's disease, a common human malignant lymphoma, is still unresolved. As a unique characteristic, we have identified constitutive activation of the transcription factor nuclear factor (NF)-kappaB p50-RelA in Hodgkin/Reed-Sternberg (H/RS) cells, which discriminates these neoplastic cells from most cell types studied to date. In contrast to other lymphoid and nonlymphoid cell lines tested, proliferation of H/RS cells depended on activated NF-kappaB. Furthermore, constitutive NF-kappaB p50-RelA prevented Hodgkin's lymphoma cells from undergoing apoptosis under stress conditions. Consistent with this dual function, Hodgkin's lymphoma cells depleted of constitutive nuclear NF-kappaB revealed strongly impaired tumor growth in severe combined immunodeficient mice. Our findings identify NF-kappaB as an important component for understanding the pathogenesis of Hodgkin's disease and for developing new therapeutic strategies against it.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vermes, I., Haanen, C., Steffens-Nakken, H., & Reutellingsperger, C. (1995) · Journal of Immunological Methods · doi:10.1016/0022-1759(95)00072-i · Cited by 5,410
Function and Activation of NF-kappaB in the Immune System
Baeuerle, P. A., & Henkel, T. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.001041 · Cited by 4,745
An Essential Role for NF-κB in Preventing TNF-α-Induced Cell Death
Beg, A. A., & Baltimore, D. (1996) · Science · doi:10.1126/science.274.5288.782 · Cited by 3,047
TNF- and Cancer Therapy-Induced Apoptosis: Potentiation by Inhibition of NF-κB
Wang, C.-Y., Mayo, M. W., & Baldwin, A. S. (1996) · Science · doi:10.1126/science.274.5288.784 · Cited by 2,617
Suppression of TNF-α-Induced Apoptosis by NF-κB
Van Antwerp, D. J., Martin, S. J., Kafri, T., Green, D. R., & Verma, I. M. (1996) · Science · doi:10.1126/science.274.5288.787 · Cited by 2,581
Structure, Regulation and Function of NF-kappaB
Siebenlist, U., Franzoso, G., & Brown, K. (1994) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.10.110194.002201 · Cited by 2,075
Liu, Z.-G., Hsu, H., Goeddel, D. V., & Karin, M. (1996) · Cell · doi:10.1016/s0092-8674(00)81375-6 · Cited by 1,937
Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB
Beg, A. A., Sha, W. C., Bronson, R. T., Ghosh, S., & Baltimore, D. (1995) · Nature · doi:10.1038/376167a0 · Cited by 1,825
Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation.
Verma, I. M., Stevenson, J. K., Schwarz, E. M., Van Antwerp, D., & Miyamoto, S. (1995) · Genes & Development · doi:10.1101/gad.9.22.2723 · Cited by 1,724
Collins, T., Read, M. A., Neish, A. S., Whitley, M. Z., Thanos, D., & Maniatis, T. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.10.7542214 · Cited by 1,718
Cited by
Regulation and Function of NF-κB Transcription Factors in the Immune System
Vallabhapurapu, S., & Karin, M. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132641 · Cited by 2,588
NF-κB in cancer: from innocent bystander to major culprit
Karin, M., Cao, Y., Greten, F. R., & Li, Z.-W. (2002) · Nature Reviews Cancer · doi:10.1038/nrc780 · Cited by 2,478
Surh, Y.-J., Chun, K.-S., Cha, H.-H., Han, S. S., Keum, Y.-S., Park, K.-K., & Lee, S. S. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00183-x · Cited by 1,620
Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB
Baldwin, A. S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11991 · Cited by 1,434
NF-κB Controls Cell Growth and Differentiation through Transcriptional Regulation of Cyclin D1
Guttridge, D. C., Albanese, C., Reuther, J. Y., Pestell, R. G., & Baldwin, A. S. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.8.5785 · Cited by 1,312
Control of apoptosis by Rel/NF-κB transcription factors
Barkett, M., & Gilmore, T. D. (1999) · Oncogene · doi:10.1038/sj.onc.1203238 · Cited by 1,204
How NF-κB is activated: the role of the IκB kinase (IKK) complex
Karin, M. (1999) · Oncogene · doi:10.1038/sj.onc.1203219 · Cited by 1,156
Aberrant rel/nfkb genes and activity in human cancer
Rayet, B., & Gélinas, C. (1999) · Oncogene · doi:10.1038/sj.onc.1203221 · Cited by 1,110
Davis, R. E., Brown, K. D., Siebenlist, U., & Staudt, L. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.12.1861 · Cited by 1,051
Huber, M. A., Azoitei, N., Baumann, B., Grünert, S., Sommer, A., Pehamberger, H., Kraut, N., Beug, H., & Wirth, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421358 · Cited by 1,033
NF-κB as a Therapeutic Target in Multiple Myeloma
Hideshima, T., Chauhan, D., Richardson, P., Mitsiades, C., Mitsiades, N., Hayashi, T., Munshi, N., Dang, L., Castro, A., Palombella, V., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200360200 · Cited by 893
Aggarwal, B. B., Vijayalekshmi, R. V., & Sung, B. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0149 · Cited by 795
Hinz, M., Krappmann, D., Eichten, A., Heder, A., Scheidereit, C., & Strauss, M. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.4.2690 · Cited by 788
Self-citationTo be, or not to be: NF-κB is the answer – role of Rel/NF-κB in the regulation of apoptosis
Kucharczak, J., Simmons, M. J., Fan, Y., & Gélinas, C. (2003) · Oncogene · doi:10.1038/sj.onc.1207230 · Cited by 769
The Rel/NF-κB Family Directly Activates Expression of the Apoptosis Inhibitor Bcl-x L
Chen, C., Edelstein, L. C., & Gélinas, C. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.8.2687-2695.2000 · Cited by 760
Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells
Guzman, M. L., Neering, S. J., Upchurch, D., Grimes, B., Howard, D. S., Rizzieri, D. A., Luger, S. M., & Jordan, C. T. (2001) · Blood · doi:10.1182/blood.v98.8.2301 · Cited by 758
Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression
Bassères, D. S., & Baldwin, A. S. (2006) · Oncogene · doi:10.1038/sj.onc.1209942 · Cited by 667
The Beginning of the End: IκB Kinase (IKK) and NF-κB Activation
Karin, M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.39.27339 · Cited by 640
Helbig, G., Christopherson, K. W., Bhat-Nakshatri, P., Kumar, S., Kishimoto, H., Miller, K. D., Broxmeyer, H. E., & Nakshatri, H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300609200 · Cited by 639
Transcriptional Cross Talk between NF-κB and p53
Webster, G. A., & Perkins, N. D. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3485 · Cited by 598
Surh, Y.-J. (2002) · Food and Chemical Toxicology · doi:10.1016/s0278-6915(02)00037-6 · Cited by 577
Epstein–Barr virus and oncogenesis: from latent genes to tumours
Young, L. S., & Murray, P. G. (2003) · Oncogene · doi:10.1038/sj.onc.1206556 · Cited by 556
NF-κB as a therapeutic target in cancer
Orlowski, R. Z., & Baldwin, A. S. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02375-4 · Cited by 553
Mutations in the NF-κB signaling pathway: implications for human disease
Courtois, G., & Gilmore, T. D. (2006) · Oncogene · doi:10.1038/sj.onc.1209939 · Cited by 525
Nuclear factor-kappa B and cancer: its role in prevention and therapy
Bharti, A. C., & Aggarwal, B. B. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01154-1 · Cited by 510
The role of cytokines in classical Hodgkin lymphoma
Skinnider, B. F., & Mak, T. W. (2002) · Blood · doi:10.1182/blood-2002-01-0099 · Cited by 505
Staudt, L. M. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000109 · Cited by 485
Cao, Y., Bonizzi, G., Seagroves, T. N., Greten, F. R., Johnson, R., Schmidt, E. V., & Karin, M. (2001) · Cell · doi:10.1016/s0092-8674(01)00599-2 · Cited by 482
TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma
Schmitz, R., Hansmann, M.-L., Bohle, V., Martin-Subero, J. I., Hartmann, S., Mechtersheimer, G., Klapper, W., Vater, I., Giefing, M., Gesk, S., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090528 · Cited by 481
Cogswell, P. C., Guttridge, D. C., Funkhouser, W. K., & Baldwin, A. S. (2000) · Oncogene · doi:10.1038/sj.onc.1203412 · Cited by 452
Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines
Mukhopadhyay, A., Bueso-Ramos, C., Chatterjee, D., Pantazis, P., & Aggarwal, B. B. (2001) · Oncogene · doi:10.1038/sj.onc.1204997 · Cited by 441
Nuclear transcription factor-κB as a target for cancer drug development
Garg, A., & Aggarwal, B. (2002) · Leukemia · doi:10.1038/sj.leu.2402482 · Cited by 441
NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells
Bentires-Alj, M., Barbu, V., Fillet, M., Chariot, A., Relic, B., Jacobs, N., Gielen, J., Merville, M.-P., & Bours, V. (2003) · Oncogene · doi:10.1038/sj.onc.1206056 · Cited by 430
Nuclear Factor-κB Activation: From Bench to Bedside
Sethi, G., Sung, B., & Aggarwal, B. B. (2008) · Experimental Biology and Medicine · doi:10.3181/0707-mr-196 · Cited by 417
NF-κB as a primary regulator of the stress response
Mercurio, F., & Manning, A. M. (1999) · Oncogene · doi:10.1038/sj.onc.1203174 · Cited by 411
Aberrant NF-κB signaling in lymphoma: mechanisms, consequences, and therapeutic implications
Jost, P. J., & Ruland, J. (2007) · Blood · doi:10.1182/blood-2006-07-025809 · Cited by 408
Current insights into the regulation of programmed cell death by NF-κB
Dutta, J., Fan, Y., Gupta, N., Fan, G., & Gélinas, C. (2006) · Oncogene · doi:10.1038/sj.onc.1209938 · Cited by 407
NEW EMBO MEMBER'S REVIEW: NF-kappaB and virus infection: who controls whom
Santoro, M. G. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg267 · Cited by 396
Jundt, F., Anagnostopoulos, I., Förster, R., Mathas, S., Stein, H., & Dörken, B. (2002) · Blood · doi:10.1182/blood.v99.9.3398 · Cited by 394
Endostatin's Antiangiogenic Signaling Network
Abdollahi, A., Hahnfeldt, P., Maercker, C., Gröne, H.-J., Debus, J., Ansorge, W., Folkman, J., Hlatky, L., & Huber, P. E. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00102-9 · Cited by 393
A requirement for NF-kappa B activation in Bcr-Abl-mediated transformation
Reuther, J. Y., Reuther, G. W., Cortez, D., Pendergast, A. M., & Baldwin Jr., A. S. (1998) · Genes & Development · doi:10.1101/gad.12.7.968 · Cited by 392
NF-κB and IKK as therapeutic targets in cancer
Kim, H. J., Hawke, N., & Baldwin, A. S. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401877 · Cited by 391
NF-κB and cancer: how intimate is this relationship
Prasad, S., Ravindran, J., & Aggarwal, B. B. (2010) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-009-0267-2 · Cited by 385
Mathas, S., Hinz, M., Anagnostopoulos, I., Krappmann, D., Lietz, A., Jundt, F., Bommert, K., Mechta‐Grigoriou, F., Stein, H., Dörken, B., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf389 · Cited by 375
Self-citationBrune, V., Tiacci, E., Pfeil, I., Döring, C., Eckerle, S., van Noesel, C. J. M., Klapper, W., Falini, B., von Heydebreck, A., Metzler, D., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080809 · Cited by 360
NF-κB in cancer: a marked target
Lin, A., & Karin, M. (2003) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00128-1 · Cited by 355
The role of chalcones in suppression of NF-κB-mediated inflammation and cancer
Yadav, V. R., Prasad, S., Sung, B., & Aggarwal, B. B. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2010.12.006 · Cited by 339
Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IκBα
Cabannes, E., Khan, G., Aillet, F., Jarrett, R. F., & Hay, R. T. (1999) · Oncogene · doi:10.1038/sj.onc.1202893 · Cited by 334
Spina, V., Bruscaggin, A., Cuccaro, A., Martini, M., Di Trani, M., Forestieri, G., Manzoni, M., Condoluci, A., Arribas, A., Terzi-Di-Bergamo, L., et al. (2018) · Blood · doi:10.1182/blood-2017-11-812073 · Cited by 332
The transcription factor NF-κB: control of oncogenesis and cancer therapy resistance
Mayo, M. W., & Baldwin, A. S. (2000) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(00)00002-0 · Cited by 324
DiMango, E., Ratner, A. J., Bryan, R., Tabibi, S., & Prince, A. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2865 · Cited by 323
Pham, L. V., Tamayo, A. T., Yoshimura, L. C., Lo, P., & Ford, R. J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.1.88 · Cited by 320
Nasopharyngeal carcinoma—Review of the molecular mechanisms of tumorigenesis
Chou, J., Lin, Y., Kim, J., You, L., Xu, Z., He, B., & Jablons, D. M. (2008) · Head & Neck · doi:10.1002/hed.20833 · Cited by 317
Allport, V. C. (2001) · Molecular Human Reproduction · doi:10.1093/molehr/7.6.581 · Cited by 307
Senescence, apoptosis and therapy — cutting the lifelines of cancer
Schmitt, C. A. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1044 · Cited by 295
“gov/cancerinfo/pdq/treatment/adulthodgkins/healthprofessional/">Hodgkin's disease and diffuse large-B-cell lymphom”
Patel, N. M., Nozaki, S., Shortle, N. H., Bhat-Nakshatri, P., Newton, T. R., Rice, S., Gelfanov, V., Boswell, S. H., Goulet, R. J., Sledge, G. W., et al. (2000) · Oncogene · doi:10.1038/sj.onc.1203768 · Cited by 294
Nuclear Factor-κB in Development, Prevention, and Therapy of Cancer
Van Waes, C. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2221 · Cited by 292
Joyce, D., Bouzahzah, B., Fu, M., Albanese, C., D'Amico, M., Steer, J., Klein, J. U., Lee, R. J., Segall, J. E., Westwick, J. K., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.36.25245 · Cited by 287
Küppers, R., Engert, A., & Hansmann, M.-L. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61245 · Cited by 286
Clonal Deleterious Mutations in the Iκbα Gene in the Malignant Cells in Hodgkin's Lymphoma
Jungnickel, B., Staratschek-Jox, A., Bräuninger, A., Spieker, T., Wolf, J., Diehl, V., Hansmann, M.-L., Rajewsky, K., & Küppers, R. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.2.395 · Cited by 283
Modulation of NF-κB Activity and Apoptosis in Chronic Lymphocytic Leukemia B Cells
Furman, R. R., Asgary, Z., Mascarenhas, J. O., Liou, H.-C., & Schattner, E. J. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.4.2200 · Cited by 278
Chemosensitization and Radiosensitization of Tumors by Plant Polyphenols
Garg, A. K., Buchholz, T. A., & Aggarwal, B. B. (2005) · Antioxidants & Redox Signaling · doi:10.1089/ars.2005.7.1630 · Cited by 278
Emdad, L., Sarkar, D., Su, Z.-Z., Randolph, A., Boukerche, H., Valerie, K., & Fisher, P. B. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3029 · Cited by 276
Molecular mechanisms of constitutive NF-κB/Rel activation in Hodgkin/Reed-Sternberg cells
Krappmann, D., Emmerich, F., Kordes, U., Scharschmidt, E., Dörken, B., & Scheidereit, C. (1999) · Oncogene · doi:10.1038/sj.onc.1202351 · Cited by 271
Self-citationNuclear factor-κB is upregulated in colorectal cancer
Lind, D. S., Hochwald, S. N., Malaty, J., Rekkas, S., Hebig, P., Mishra, G., Moldawer, L. L., Copeland, E. M., & MacKay, S. (2001) · Surgery · doi:10.1067/msy.2001.116672 · Cited by 269
Hinz, M., Lemke, P., Anagnostopoulos, I., Hacker, C., Krappmann, D., Mathas, S., Dörken, B., Zenke, M., Stein, H., & Scheidereit, C. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020062 · Cited by 266
Self-citationPianetti, S., Arsura, M., Romieu-Mourez, R., Coffey, R. J., & Sonenshein, G. E. (2001) · Oncogene · doi:10.1038/sj.onc.1204257 · Cited by 265
Transcription factor NF-κB is constitutively activated in acute lymphoblastic leukemia cells
Kordes, U., Krappmann, D., Heissmeyer, V, Ludwig, W., & Scheidereit, C. (2000) · Leukemia · doi:10.1038/sj.leu.2401705 · Cited by 264
Self-citationKumagai, Y., & Sumi, D. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105144 · Cited by 262
Emmerich, F., Meiser, M., Hummel, M., Demel, G., Foss, H.-D., Jundt, F., Mathas, S., Krappmann, D., Scheidereit, C., Stein, H., et al. (1999) · Blood · doi:10.1182/blood.v94.9.3129 · Cited by 261
Self-citationHinz, M., Löser, P., Mathas, S., Krappmann, D., Dörken, B., & Scheidereit, C. (2001) · Blood · doi:10.1182/blood.v97.9.2798 · Cited by 261
Self-citationThe Biology of Human Lymphoid Malignancies Revealed by Gene Expression Profiling
Staudt, L. M., & Dave, S. (2005) · Advances in Immunology · doi:10.1016/s0065-2776(05)87005-1 · Cited by 260
Müerköster, S., Wegehenkel, K., Arlt, A., Witt, M., Sipos, B., Kruse, M.-L., Sebens, T., Klöppel, G., Kalthoff, H., Fölsch, U. R., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1860 · Cited by 254
Gao, X., Xu, Y. X., Janakiraman, N., Chapman, R. A., & Gautam∗, S. C. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00775-4 · Cited by 252
Asai, T., Tomita, Y., Nakatsuka, S., Hoshida, Y., Myoui, A., Yoshikawa, H., & Aozasa, K. (2002) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2002.tb02172.x · Cited by 155
You, Z., Ouyang, H., Lopatin, D., Polver, P. J., & Wang, C.-Y. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102464200 · Cited by 127
The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma
Vrábel, D., Pour, L., & Ševčíková, S. (2019) · Blood Reviews · doi:10.1016/j.blre.2018.11.003 · Cited by 123
Metadata
- Authors
- Bargou, R. C., Emmerich, F., Krappmann, D., Bommert, K., Mapara, M. Y., Arnold, W., Royer, H. D., Grinstein, E., Greiner, A., Scheidereit, C., & Dörken, B.
- Venue
- Journal of Clinical Investigation
- Published
- 1997-12-15
- Volume
- 100
- Issue
- 12
- Pages
- 2961-2969
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2086941505
- Cited by
- 761
- References
- 45
- FWCI
- 12.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.